K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 | PFIZER INC.PFE | 47 | $46.8M |
| 2 | GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 | META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 | AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 | LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 | FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 | ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 | ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 | AMGEN INCAMGN | 19 | $24.9M |
| 11 | COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 | MERCK & CO INCMRK | 14 | $24.0M |
| 13 | SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 | GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 | APPLE INCAAPL | 9 | $22.1M |
| 16 | T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 | UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 | VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 | OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 | MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 | QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 | GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 | BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 | ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | METAMeta Platforms Inc. | 129 | $50.2M |
| 2 | PFEPfizer Inc. | 87 | $48.6M |
| 3 | GMGeneral Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZNAmazon.com Inc. | 80 | $35.3M |
| 6 | LMTLockheed Martin Corporation | 88 | $29.4M |
| 7 | FDXFedEx Corporation | 82 | $28.3M |
| 8 | LLYEli Lilly and Company | 83 | $28.1M |
| 9 | AMGNAmgen Inc. | 95 | $28.0M |
| 10 | MRKMerck & Co. Inc. | 92 | $27.5M |
| 11 | AAPLApple Inc. | 64 | $26.8M |
| 12 | GOOGLAlphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SOSouthern Company | 108 | $26.1M |
| 15 | UNHUnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZVerizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 | CHTR | 137 | $22.6M |
| 19 | GDGeneral Dynamics Corporation | 127 | $22.5M |
| 20 | TAT&T Inc. | 134 | $21.6M |
| 21 | ORCLOracle Corporation | 132 | $20.6M |
| 22 | CMCSAComcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXYOccidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFTMicrosoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · JOHNSON & JOHNSON SERVICES INC
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $3.5M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Acc |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 and FY27 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 General issues related to third party litigation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2026-04-17 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $50K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 59A, 951A, 250, 163(j), and 174. |
| 2026-04-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | |
| 2026-04-15 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.5M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Acc |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 General issues related to third party litigation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $40K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302). |
| 2026-01-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2026-01-08 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | |
| 2026-01-07 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $2.5M | Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - Issues related to USMCA review and renegotiation - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $10K | Bankruptcy Law. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2025-10-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $50K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605). |
| 2025-10-06 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.0M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954, Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - Issues related t |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. H.R.1 - One Big Beautiful Bill Act. Issues related to the FY26 budget and appropriations process. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605). |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $20K | Bankruptcy Law. |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 7060). |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | Bankruptcy Law. |
| 2025-07-10 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2025-07-09 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $3.3M | - Issues related to the SUPPORT Act Issues related to - artificial intelligence - data privacy - cybersecurity - robotics Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills - Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. XXXX/ S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, H.R. XXX HELP Copays Act, regarding all provisions - H.R. 2214/ S. XXXX Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - PL117-169 The Inflation Reduction Act, regarding all provisions rel |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to the FY25 budget and appropriations process; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025. Issues related to the FY26 budget and appropriations process. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), 174 and 41 (H.R. 1990, H.R. 574, S. 187, H.R. 1062). Issues related to interest deductibility. (H.R. 1347, S. 559) |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $20K | Bankruptcy Law. |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $20K | |
| 2025-04-11 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.5M | Issues related to: - Contact lens safety, peripheral artery disease, and stroke care, specifically to provisions regarding appropriations report language - Appropriations for Labor Health and Human Services - NIH funding - S 1375/HR 830, "HELP Copays Act", regarding all provisions. - PL 117-169, "The Inflation Reduction Act", regarding provisions impacting drug pricing and implementation. - PL 113-5 "Pandemic All Hazards Preparedness Reauthorization", regarding all provisions. - S 1355/HR 2940, "PASTEUR Act", regarding all provisions. - HR 3723, "Medical Device Electronic Labeling Act", regarding all provisions. - HR 2748, "Contact Lens Prescription Verification Modernization Act", regarding all provisions. - HR 4261, "Amputation Reduction and Compassion Act", regarding all provisions. - S 3131/HR 5539, "ORPHAN Cures Act", regarding all provisions. - HR 5372, "Expanding Access to Seniors Access to Lower Cost Medicines Act of 2023", regarding all provisions. - S 2305, "The Biosimilar |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $50K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. S.3679/H.R.7153 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act Issues related to cybersecurity for healthcare, including S.5218, the Health Infrastructure Security and Accountability Act of 2024. Issues related to the FY25 budget and appropriations process, including H.R. 10445, the Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, and H.R.10545, the American Relief Act, 2025. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | Bankruptcy Law |
PFIZER INC.
GENERAL MOTORS COMPANY
META PLATFORMS INC. AND VARIOUS SUBSIDIARIES
AMAZON.COM SERVICES LLC
LOCKHEED MARTIN CORPORATION
FEDEX CORPORATION
ELI LILLY AND COMPANY
ALTRIA CLIENT SERVICES LLC
AMGEN INC
COMCAST CORPORATION
MERCK & CO INC
SOUTHERN COMPANY
GOOGLE CLIENT SERVICES LLC
APPLE INC
T-MOBILE USA INC.
UNITEDHEALTH GROUP INC
VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIES
OCCIDENTAL PETROLEUM CORPORATION
MICROSOFT CORPORATION
QUALCOMM INCORPORATED
GENERAL DYNAMICS CORP
BOEING COMPANY
ORACLE CORPORATION
CHTR
T